Generation of Antibodies Selectively Recognizing Epitopes in a Formaldehyde-Fixed Cell-Surface Antigen Using Virus-like Particle Display and Hybridoma Technology.

antibody discovery antigen display cell-surface antigen formaldehyde-fixed paraffin-embedded (FFPE) tissue samples hybridoma technology nerve growth factor receptor virus-like particles

Journal

Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489

Informations de publication

Date de publication:
05 Sep 2023
Historique:
received: 08 08 2023
revised: 23 08 2023
accepted: 25 08 2023
medline: 27 9 2023
pubmed: 27 9 2023
entrez: 27 9 2023
Statut: epublish

Résumé

Efficient induction of target-specific antibodies can be elicited upon immunization with highly immunogenic virus-like particles (VLPs) decorated with desired membrane-anchored target antigens (Ags). However, for example, for diagnostic purposes, monoclonal antibodies (mAbs) are required to enable the histological examination of formaldehyde-fixed paraffin-embedded (FFPE) biopsy tissue samples. Aiming at the generation of FFPE-antigen-specific mAbs and as a proof of concept (POC), we first established a simplified protocol using only formaldehyde and 90 °C heat fixation (FF90) of cells expressing the target Ag nerve growth factor receptor (NGFR). The FF90 procedure was validated using flow cytometric analysis and two mAbs recognizing either the native and FFPE-Ag or exclusively the native Ag. C-terminally truncated NGFR (trNGFR)-displaying native and FF90-treated VLPs derived from HIV-1 did not reveal distinctive changes in particle morphology using transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis. Mice were subsequently repetitively immunized with trNGFR-decorated FF90-VLPs and hybridoma technology was used to establish mAb-producing cell clones. In multiple screening rounds, nine cell clones were identified producing mAbs distinctively recognizing epitopes in FF90- and FFPE-NGFR. This POC of a new methodology should foster the future generation of mAbs selectively targeting FFPE-fixed cell-surface Ags.

Identifiants

pubmed: 37753971
pii: antib12030057
doi: 10.3390/antib12030057
pmc: PMC10525569
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : German Federal Ministry of Education and Research
ID : 13FH242PX6, 13FH767IA6

Références

PLoS One. 2012;7(10):e48421
pubmed: 23110238
Elife. 2018 Jul 11;7:
pubmed: 29993362
J Ind Microbiol Biotechnol. 2012 Aug;39(8):1189-98
pubmed: 22526329
Mol Immunol. 2009 Jun;46(10):1988-2001
pubmed: 19376580
Methods Mol Biol. 2023;2681:361-371
pubmed: 37405658
Cytometry A. 2004 Dec;62(2):169-73
pubmed: 15536642
Virology. 2019 May;531:40-47
pubmed: 30852270
Virol J. 2012 Sep 18;9:210
pubmed: 22988963
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1531-6
pubmed: 21205896
Expert Rev Vaccines. 2022 Apr;21(4):453-469
pubmed: 35023430
Hum Vaccin Immunother. 2017 Nov 2;13(11):2594-2605
pubmed: 28854003
Vet Pathol. 2014 Jan;51(1):42-87
pubmed: 24129895
Biotechnol Bioeng. 2021 Jul;118(7):2660-2675
pubmed: 33844274
J Virol. 2016 Aug 26;90(18):8074-84
pubmed: 27356903
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Biotechnol J. 2018 Mar;13(3):e1700345
pubmed: 29131519
Methods Mol Biol. 2020;2070:351-361
pubmed: 31625106
Cancer Sci. 2022 Aug;113(8):2878-2887
pubmed: 35343032
Virology. 2022 Mar;568:41-48
pubmed: 35101772
Sci Rep. 2021 Nov 12;11(1):22154
pubmed: 34773059
Am J Surg Pathol. 2000 Jul;24(7):1016-9
pubmed: 10895825
Mol Ther Methods Clin Dev. 2019 Mar 16;13:371-379
pubmed: 30997367
Hum Gene Ther. 1998 Sep 20;9(14):2005-18
pubmed: 9759928
Cell. 1997 Nov 14;91(4):501-10
pubmed: 9390559
Biotech Histochem. 2018;93(5):373-386
pubmed: 30113239
Vet Immunol Immunopathol. 2019 Dec;218:109939
pubmed: 31526954
Biol Blood Marrow Transplant. 1999;5(4):215-21
pubmed: 10465101
J Neurochem. 2019 Jan;148(2):238-251
pubmed: 30308090
Virology. 2007 Jun 5;362(2):331-41
pubmed: 17276476
Nat Genet. 2009 Jun;41(6):753-61
pubmed: 19412179
J Vis Exp. 2022 Feb 10;(180):
pubmed: 35225285
Vaccine. 2016 Mar 18;34(13):1634-1641
pubmed: 26795367
J Oral Maxillofac Pathol. 2012 Sep;16(3):400-5
pubmed: 23248474
EMBO J. 2007 Apr 18;26(8):2218-26
pubmed: 17396149

Auteurs

Stefanie Schatz (S)

Research Group Medical Biotechnology and Bioengineering, Faculty of Applied Natural Sciences, University of Applied Sciences Cologne, Campusplatz 1, 51379 Leverkusen, Germany.
Institute of Technical Chemistry, Gottfried Wilhelm Leibniz University Hannover, Calinstrasse 3-9, 30167 Hannover, Germany.

Lena Willnow (L)

Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany.

Monika Winkels (M)

Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany.

Jamila Franca Rosengarten (JF)

Research Group Medical Biotechnology and Bioengineering, Faculty of Applied Natural Sciences, University of Applied Sciences Cologne, Campusplatz 1, 51379 Leverkusen, Germany.
Institute of Technical Chemistry, Gottfried Wilhelm Leibniz University Hannover, Calinstrasse 3-9, 30167 Hannover, Germany.

Benjamin Theek (B)

Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany.

Ian C D Johnston (ICD)

Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany.

Jörn Stitz (J)

Research Group Medical Biotechnology and Bioengineering, Faculty of Applied Natural Sciences, University of Applied Sciences Cologne, Campusplatz 1, 51379 Leverkusen, Germany.

Classifications MeSH